The use of gastrin in the treatment of diabetes
CA 2326741 A1 · Owner: Rtp Pharma Inc. · Inventors: Parikh, Indu; Lane, Anne; Brand, Stephen J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods and compositions for treating diabetes mellitus in a patient in need thereof are provided. The methods include administering to a patient a composition providing a gastrin/CCK receptor ligand e.g. a gastrin, and/or , an epidermal growth factor (EGF) receptor ligand e.g. TGF-.alpha. in an , amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene e.g. a preprogastrin , peptide precursor gene and an EGF receptor ligand gene e.g. a TGF-.alpha. , gene. The methods …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 27, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 27, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 27, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.